

## Cell And Gene Therapy Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, II, III, IV), By Indication (Oncology, CNS), By Region (Asia Pacific, North America), And Segment Forecasts, 2022 - 2030

https://marketpublishers.com/r/C6FCBBEF9521EN.html

Date: June 2022

Pages: 275

Price: US\$ 5,950.00 (Single User License)

ID: C6FCBBEF9521EN

## **Abstracts**

This report can be delivered to the clients within 3 Business Days

Cell And Gene Therapy Clinical Trials Market Growth & Trends

The global cell and gene therapy clinical trials market size is expected to reach USD 24.5 billion by 2030, registering a CAGR of 14.6% during the forecast period, according to a new report by Grand View Research, Inc. Cell and gene therapy (CGTs) signify the next great movement of therapeutic innovation and have resulted in the development of promising therapies around the world. Although a few of the early therapies have got marketing approval in the U.S., there are numerous promising therapies in development across the world. During the pandemic, the majority of clinical studies were focused on COVID-19. However, owing to the decline in COVID-19 cases, the market players are now shifting their focus to the development of CGTs.

For instance, in February 2022, the life sciences company, Cytiva, collaborated with NecstGen to develop gene therapies. Such collaborations are likely to promote market growth post-pandemic. The market has witnessed significant growth over the past few years, with a rise in the CGT pipeline. As reported by Global Data, in March 2021, over 2,400 CGT drugs were in the pipeline, whereas in 2020 there were over 551 CGT drugs in the clinical phase. In addition, investment is rolling into companies of various types, ranging from startups to major acquisitions by significant biopharmaceutical companies. In 2019, 19 deals of M&A worth over USD 156 billion were completed.



The largest of these was the acquisition of Celgene and its pipeline of numerous cell therapy assets for oncology treatment by Bristol-Myers Squibb for USD 74 billion. Such deals are likely to improve the market growth as CGT is gaining popularity in the treatment of life-threatening diseases. Research funding in CGT has improved in the post-pandemic period. For instance, in January 2022, researchers at the University of York received a grant of USD 3.1 million to support stem cell gene therapy research to treat sickle cell disease. In March 2022, researchers at the Indiana University School received funding of USD 12 million to develop safe gene therapy for treating hemophilia. Such investments are likely to have a positive impact on market growth.

Cell And Gene Therapy Clinical Trials Market Report Highlights

The phase II segment accounted for the largest share in 2021 owing to a large number of therapies currently in development in phase II

The oncology indication segment accounted for the largest share in 2021 as a high number of CGT trials are focused on the treatment of cancer

North America dominated the global market in 2021. This is largely attributed to a large number of clinical trial activities in the U.S. and favorable government support

Asia Pacific is expected to register the fastest CAGR over the forecast period owing to the increasing number of biotechnology companies focusing on CGTs



## **Contents**

#### **Table Of Contents**

#### **CHAPTER 1 METHODOLOGY AND SCOPE**

- 1.1 Market Segmentation & Scope
  - 1.1.1 Phase
  - 1.1.2 Indication
  - 1.1.3 Regional Scope
  - 1.1.4 Estimates And Forecast Timeline
- 1.2 Research Methodology
- 1.3 Information Procurement
  - 1.3.1 Purchased Database
  - 1.3.2 Gvr's Internal Database
  - 1.3.3 Secondary Sources
  - 1.3.4 Primary Research
  - 1.3.5 Details Of Primary Research
- 1.4 Information Or Data Analysis
  - 1.4.1 Data Analysis Models
- 1.5 Market Formulation & Validation
- 1.6 Model Details
  - 1.6.1 Commodity Flow Analysis
- 1.7 List Of Secondary Sources
- 1.8 List Of Primary Sources
- 1.9 List Of Abbreviations
- 1.10 Objectives
  - 1.10.1 Objective -
  - 1.10.2 Objective -
  - 1.10.3 Objective -
  - 1.10.4 Objective -

## **CHAPTER 2 EXECUTIVE SUMMARY**

- 2.1 Market Outlook
- 2.2 Competitive Insights

# CHAPTER 3 CELL AND GENE THERAPY CLINICAL TRIALS MARKET: VARIABLES, TRENDS, & SCOPE



- 3.1 Market Lineage Outlook
  - 3.1.1 Parent Market Outlook
  - 3.1.2 Ancillary Market Outlook
- 3.2 Penetration & Growth Prospect Mapping
- 3.3 COVID-19 Pandemic Impact On Clinical Trial Activity
  - 3.3.1 Disrupted Clinical Trials
- 3.3.1.1 Troubleshooting The Manufacturing & Supply Challenges Associated To COVID-19
  - 3.3.1.2 Other Challenges
- 3.4 Market Dynamics
  - 3.4.1 Market Driver Analysis
  - 3.4.1.1 Growing Interest In Cell And Gene Therapy
  - 3.4.1.2 Adoption Of New Technology In Clinical Research
  - 3.4.1.3 Increasing Investments And R&D Funding
  - 3.4.2 Market Restraint Analysis
    - 3.4.2.1 Recruitment Obstacles
  - 3.4.3 Industry Challenges
    - 3.4.3.1 Rising Cost Of Clinical Trial
  - 3.4.4 Major Deals & Strategic Alliances Analysis
    - 3.4.4.1 Product/Service Launch
    - 3.4.4.2 Merger & Acquisition
    - 3.4.4.3 Collaboration & Partnership
    - 3.4.4.4 Research Expansion
    - 3.4.4.5 Service Expansion
  - 3.4.5 Regulatory Framework
  - 3.4.6 U.S.
  - 3.4.7 Europe
  - 3.4.8 China
    - 3.4.8.1 Regulatory Challenges & Risk Of Selling Unapproved Cell Therapies
  - 3.4.9 Japan
- 3.5 Cell And Gene Therapy Clinical Trials Market Analysis Tools
  - 3.5.1 Porter's Five Forces Analysis
  - 3.5.2 PESTEL Analysis

## CHAPTER 4 CELL AND GENE THERAPY CLINICAL TRIALS MARKET: PHASE SEGMENT ANALYSIS

4.1 Cell And Gene Therapy Clinical Trials: Market Share Analysis, 2021 & 2030



- 4.2 Phase I
  - 4.2.1 Phase I Market, 2018 2030 (USD Million)
- 4.3 Phase II
  - 4.3.1 Phase II Market, 2018 2030 (USD Million)
- 4.4 Phase III
  - 4.4.1 Phase III Market, 2018 2030 (USD Million)
- 4.5 Phase IV
  - 4.5.1 Phase IV Market, 2018 2030 (USD Million)

## CHAPTER 5 CELL AND GENE THERAPY CLINICAL TRIALS MARKET: INDICATION SEGMENT ANALYSIS

- 5.1 Cell And Gene Therapy Clinical Trials: Market Share Analysis, 2021 & 2030
- 5.2 Oncology
- 5.2.1 Oncology Market, 2018 2030 (USD Million)
- 5.3 Cardiology
  - 5.3.1 Cardiology Market, 2018 2030 (Usd Million)
- **5.4 CNS** 
  - 5.4.1 CNS Market, 2018 2030 (USD Million)
- 5.5 Musculoskeletal
  - 5.5.1 Musculoskeletal Market, 2018 2030 (USD Million)
- 5.6 Infectious Diseases
  - 5.6.1 Infectious Diseases Market, 2018 2030 (USD Million)
- 5.7 Dermatology
  - 5.7.1 Dermatology Market, 2018 2030 (USD Million)
- 5.8 Endocrine, Metabolic, Genetic
  - 5.8.1 Endocrine, Metabolic, Genetic Market, 2018 2030 (USD Million)
- 5.9 Immunology & Inflammation
  - 5.9.1 Immunology & Inflammation Market, 2018 2030 (USD Million)
- 5.10 Ophthalmology
  - 5.10.1 Ophthalmology Market, 2018 2030 (USD Million)
- 5.11 Hematology
  - 5.11.1 Haematology Market, 2018 2030 (USD Million)
- 5.12 Gastrointestinal
  - 5.12.1 Gastrointestinal Market, 2018 2030 (USD Million)
- 5.13 Others
  - 5.13.1 Others Market, 2018 2030 (USD Million)

### CHAPTER 6 CELL AND GENE THERAPY CLINICAL TRIALS MARKET: REGIONAL



### **ANALYSIS**

- 6.1 Cell And Gene Therapy Clinical Trials: Regional Market Share
- 6.2 Cell And Gene Therapy Clinical Trials: Market Share Analysis, 2021 & 2028
- 6.3 North America
- 6.3.1 North America Cell And Gene Therapy Clinical Trials Market, 2018 2030 (USD Million)
  - 6.3.2 U.S.
  - 6.3.2.1 U.S. Cell And Gene Therapy Clinical Trials Market, 2018 2030 (USD Million)
  - 6.3.3 Canada
- 6.3.3.1 Canada Cell And Gene Therapy Clinical Trials Market, 2018 2030 (USD Million)
- 6.4 Europe
  - 6.4.1 Europe Cell And Gene Therapy Clinical Trials Market, 2018 2030 (USD Million)
  - 6.4.2 U.K.
  - 6.4.2.1 U.K. Cell And Gene Therapy Clinical Trials Market, 2018 2030 (USD Million)
  - 6.4.3 Germany
- 6.4.3.1 Germany Cell And Gene Therapy Clinical Trials Market, 2018 2030 (USD Million)
  - 6.4.4 France
- 6.4.4.1 France Cell And Gene Therapy Clinical Trials Market, 2018 2030 (USD Million)
  - 6.4.5 Italy
  - 6.4.5.1 Italy Cell And Gene Therapy Clinical Trials Market, 2018 2030 (USD Million)
  - 6.4.6 Spain
- 6.4.6.1 Spain Cell And Gene Therapy Clinical Trials Market, 2018 2030 (USD Million)
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Cell And Gene Therapy Clinical Trials Market, 2018 2030 (USD Million)
  - 6.5.2 India
  - 6.5.2.1 India Cell And Gene Therapy Clinical Trials Market, 2018 2030 (USD Million)
- 6.5.3 Japan
- 6.5.3.1 Japan Cell And Gene Therapy Clinical Trials Market, 2018 2030 (USD Million)
  - 6.5.4 China
- 6.5.4.1 China Cell And Gene Therapy Clinical Trials Market, 2018 2030 (USD Million)
  - 6.5.5 Australia



- 6.5.5.1 Australia Cell And Gene Therapy Clinical Trials Market, 2018 2030 (USD Million)
  - 6.5.6 South Korea
- 6.5.6.1 South Korea Cell And Gene Therapy Clinical Trials Market, 2018 2030 (USD Million)
- 6.6 Latin America
- 6.6.1 Latin America Cell And Gene Therapy Clinical Trials Market, 2018 2030 (USD Million)
  - 6.6.2 Brazil
- 6.6.2.1 Brazil Cell And Gene Therapy Clinical Trials Market, 2018 2030 (USD Million)
  - 6.6.3 Mexico
- 6.6.3.1 Mexico Cell And Gene Therapy Clinical Trials Market, 2018 2030 (USD Million)
  - 6.6.4 Argentina
- 6.6.4.1 Argentina Cell And Gene Therapy Clinical Trials Market, 2018 2030 (USD Million)
  - 6.6.5 Colombia
- 6.6.5.1 Colombia Cell And Gene Therapy Clinical Trials Market, 2018 2030 (USD Million)
- 6.7 MEA
  - 6.7.1 MEA Cell And Gene Therapy Clinical Trials Market, 2018 2030 (USD Million)
  - 6.7.2 South Africa
- 6.7.2.1 South Africa Cell And Gene Therapy Clinical Trials Market, 2018 2030 (USD Million)
  - 6.7.3 Saudi Arabia
- 6.7.3.1 Saudi Arabia Cell And Gene Therapy Clinical Trials Market, 2018 2030 (USD Million)
  - 6.7.4 UAE
    - 6.7.4.1 UAE Cell And Gene Therapy Clinical Trials Market, 2018 2030 (USD Million)

#### **CHAPTER 7 COMPANY PROFILES**

- 7.1 Company Profiles
  - **7.1.1 ICON Plc** 
    - 7.1.1.1 Company Overview
    - 7.1.1.2 Financial Performance
    - 7.1.1.3 Product Benchmarking
    - 7.1.1.4 Strategic Initiatives



### 7.1.2 IQVIA

- 7.1.2.1 Company Overview
- 7.1.2.2 Financial Performance
- 7.1.2.3 Product Benchmarking
- 7.1.2.4 Strategic Initiatives

## 7.1.3 LABORATORY CORPORATION OF AMERICA HOLDINGS

- 7.1.3.1 Company Overview
- 7.1.3.2 Financial Performance
- 7.1.3.3 Product Benchmarking
- 7.1.3.4 Strategic Initiatives

## 7.1.4 SYNEOS HEALTH

- 7.1.4.1 Company Overview
- 7.1.4.2 Financial Performance
- 7.1.4.3 Product Benchmarking
- 7.1.4.4 Strategic Initiatives

## 7.1.5 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

- 7.1.5.1 Company Overview
- 7.1.5.2 Financial Performance
- 7.1.5.3 Product Benchmarking
- 7.1.5.4 Strategic Initiatives

## 7.1.6 MEDPACE HOLDINGS, INC.

- 7.1.6.1 Company Overview
- 7.1.6.2 Financial Performance
- 7.1.6.3 Product Benchmarking
- 7.1.6.4 Strategic Initiatives
- 7.1.7 PPD, INC.
  - 7.1.7.1 Company Overview
  - 7.1.7.2 Financial Performance
  - 7.1.7.3 Product Benchmarking
  - 7.1.7.4 Strategic Initiatives

## 7.1.8 PAREXEL INTERNATIONAL Corporation

- 7.1.8.1 Company Overview
- 7.1.8.2 Financial Performance
- 7.1.8.3 Product Benchmarking
- 7.1.8.4 Strategic Initiatives

## 7.1.9 NOVOTECH

- 7.1.9.1 Company Overview
- 7.1.9.2 Product Benchmarking
- 7.1.9.3 Strategic Initiatives



7.1.10 VERISTAT, LLC

7.1.10.1 Company Overview

7.1.10.2 Product Benchmarking

7.1.10.3 Strategic Initiatives



## **List Of Tables**

## **LIST OF TABLES**

Table 1 List of secondary sources

Table 2 List of Abbreviations

Table 3 Impact of COVID-19 on new patients entering trials

Table 4 Impact of COVID-19 on other therapeutic areas



## **List Of Figures**

## **LIST OF FIGURES**

- Fig. 1 Market research process
- Fig. 2 Information procurement
- Fig. 3 Primary research pattern
- Fig. 4 Market research approaches
- Fig. 5 QFD modeling for market share assessment
- Fig. 6 Market formulation & validation
- Fig. 7 Commodity flow analysis
- Fig. 8 Cell and gene therapy clinical trials market: Executive summary(2020)
- Fig. 9 Cell and gene therapy clinical trials market: Strategy framework
- Fig. 10 Parent market outlook
- Fig. 11 Related/ancillary market outlook
- Fig. 12 Penetration & growth prospect mapping
- Fig. 13 Companies with affected trials, by size
- Fig. 14 Affected trials, by study phase
- Fig. 15 Troubleshooting the challenges associated with COVID-19: Cell therapy development programs
- Fig. 16 Troubleshooting the challenges associated with COVID-19: Cell therapy manufacturing & delivery
- Fig. 17 Market driver relevance analysis (Current & future impact)
- Fig. 18 Market restraint relevance analysis (Current & future impact)
- Fig. 19 Porter's five forces analysis
- Fig. 20 SWOT analysis, by factor (political & legal, economic and technological)
- Fig. 21 Cell and gene therapy clinical trials market phase outlook: Segment dashboard
- Fig. 22 Cell and gene therapy clinical trials market: Phase movement analysis
- Fig. 23 Phase I market, 2018 2030 (USD Million)
- Fig. 24 Phase II market, 2018 2030 (USD Million)
- Fig. 25 Phase III market, 2018 2030 (USD Million)
- Fig. 26 Phase IV market, 2018 2030 (USD Million)
- Fig. 27 Cell and gene therapy clinical trials market indication outlook: Segment dashboard
- Fig. 28 Cell and Gene Therapy Clinical trials market: Indication movement analysis
- Fig. 29 Oncology market, 2018 2030 (USD Million)
- Fig. 30 Cardiology market, 2018 2030 (USD Million)
- Fig. 31 CNS market, 2018 2030 (USD Million)
- Fig. 32 Musculoskeletal market, 2018 2030 (USD Million)



- Fig. 33 Infectious diseases market, 2018 2030 (USD Million)
- Fig. 34 Dermatology market, 2018 2030 (USD Million)
- Fig. 35 Endocrine, metabolic, genetic market, 2018 2030 (USD Million)
- Fig. 36 Immunology & inflammation market, 2018 2030 (USD Million)
- Fig. 37 Ophthalmology market, 2018 2030 (USD Million)
- Fig. 38 Hematology market, 2018 2030 (USD Million)
- Fig. 39 Gastrointestinal market, 2018 2030 (USD Million)
- Fig. 40 Others market, 2018 2030 (USD Million)
- Fig. 41 Regional market: Key takeaways
- Fig. 42 Regional market share, 2020
- Fig. 43 Regional outlook, 2021 & 2030
- Fig. 44 North America market, 2018 2030 (USD Million)
- Fig. 45 U.S. market, 2018 2030 (USD Million)
- Fig. 46 Canada market, 2018 2030 (USD Million)
- Fig. 47 Europe market, 2018 2030 (USD Million)
- Fig. 48 U.K. market, 2018 2030 (USD Million)
- Fig. 49 Germany market, 2018 2030 (USD Million)
- Fig. 50 France market, 2018 2030 (USD Million)
- Fig. 51 Italy market, 2018 2030 (USD Million)
- Fig. 52 Spain market, 2018 2030 (USD Million)
- Fig. 53 Asia Pacific market, 2018 2030 (USD Million)
- Fig. 54 India market, 2018 2030 (USD Million)
- Fig. 55 Japan market, 2018 2030 (USD Million)
- Fig. 56 China market, 2018 2030 (USD Million)
- Fig. 57 Australia market, 2018 2030 (USD Million)
- Fig. 58 South Korea market, 2018 2030 (USD Million)
- Fig. 59 Latin America market, 2018 2030 (USD Million)
- Fig. 60 Brazil market, 2018 2030 (USD Million)
- Fig. 61 Mexico market, 2018 2030 (USD Million)
- Fig. 62 Argentina market, 2018 2030 (USD Million)
- Fig. 63 Colombia market, 2018 2030 (USD Million)
- Fig. 64 MEA market, 2018 2030 (USD Million)
- Fig. 65 South Africa market, 2018 2030 (USD Million)
- Fig. 66 Saudi Arabia market, 2018 2030 (USD Million)
- Fig. 67 UAE market, 2018 2030 (USD Million)



## I would like to order

Product name: Cell And Gene Therapy Clinical Trials Market Size, Share & Trends Analysis Report By

Phase (Phase I, II, III, IV), By Indication (Oncology, CNS), By Region (Asia Pacific, North

America), And Segment Forecasts, 2022 - 2030

Product link: <a href="https://marketpublishers.com/r/C6FCBBEF9521EN.html">https://marketpublishers.com/r/C6FCBBEF9521EN.html</a>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

## **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/C6FCBBEF9521EN.html">https://marketpublishers.com/r/C6FCBBEF9521EN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970